Drug Profile
EVT 801
Alternative Names: EVT-801Latest Information Update: 30 Oct 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Developer Evotec SE; Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Cancer
Most Recent Events
- 23 Oct 2023 Efficacy data from a phase I trial in solid tumours presented at the European Society of Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 Efficacy data from a phase I trial in Solid tumours presented at the European Society of Medical Oncology Congress (ESMO-2023)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in Germany (PO)